Australia's Arana Therapeutics has struck a deal to co-develop an experimental colorectal cancer therapy with Japan's Kyowa Hakko Kogyo. Arana will receive up to $8 million in the joint venture and the two companies will split ownership of ART104. The developers will split the development costs, with the Japanese company contributing technology to the program. Kyowa has rights to commercialize the therapy in some Asian markets.
- see the release
- check out the report from AFX
Amgen inks $520M deal with Kyowa Hakko
Kyowa Hakko receives not approvable letter